The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; 2 of the 15 sources its claims cite were checked for support.
UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82
Open accessAbstract
Aims/hypothesis The aim of this project was to build a new version of the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS-OM1), a patient-level simulation tool for predicting lifetime health outcomes of people with type 2 diabetes mellitus.Methods Data from 5,102 UKPDS patients from the 20 year trial and the 4,031 survivors entering the 10 year post-trial monitoring period were used to derive parametric proportional hazards models predicting absolute risk of diabetes complications and death. We re-estimated the seven original event equations and estimated new equations for diabetic ulcer and some second events. The additional data permitted inclusion of new risk factor predictors such as estimated GFR. We also developed four new equations for all-cause mortality. Internal validation of model predictions of cumulative incidence of all events and death was carried out and a contemporary patient-level dataset was used to compare 10 year predictions from the original and the new models.Results Model equations were based on a median 17.6 years of follow-up and up to 89,760 patient-years of data, providing double the number of events, greater precision and a larger number of significant covariates. The new model, UKPDS-OM2, is internally valid over 25 years and predicts event rates for complications, which are lower than those from the existing model.Conclusions/interpretation The new UKPDS-OM2 has significant advantages over the existing model, as it captures more outcomes, is based on longer follow-up data, and more comprehensively captures the progression of diabetes. Its use will permit detailed and reliable lifetime simulations of key health outcomes in people with type 2 diabetes mellitus.
Overview
CoChat Summary
## TL;DR
The paper develops UKPDS-OM2, a patient-level simulation model for lifetime outcomes in type 2 diabetes, using longer follow-up from 5,102 UKPDS participants and 3,984 post-trial survivors. Compared with UKPDS-OM1, the new model includes more outcomes and risk factors, shows internal validity over 25 years, and generally predicts lower event rates and longer life expectancy.
## Key findings
- The model equations were based on a median 17.6 years of follow-up and up to 89,760 patient-years of data, with at least twice as many events as in UKPDS-OM1 for each outcome; for example, 504 stroke events vs 157 in UKPDS-OM1.
- Internal validation over 25 years found simulated curves within the 95% CIs of observed cumulative failure for all events and death; predictions stabilized at around 200 Monte Carlo replications.
- In the contemporary external dataset (n = 3,984), UKPDS-OM2 predicted fewer events than UKPDS-OM1, including 10% vs 21% for myocardial infarction and 22.5% vs 31.6% for all-cause mortality; renal failure was 0.5% vs 1.3%.
- Life expectancy predictions were higher with UKPDS-OM2 for all age groups examined; for ages 50–54, remaining life expectancy was 25.1 years with UKPDS-OM2 vs 20.0 years with UKPDS-OM1, and the 95% CIs were narrower.
## Methods
- Patient-level epidemiological simulation model comparing UKPDS-OM2 with UKPDS-OM1; annual cycles estimate complications, death, life expectancy, and QALYs.
- Risk equations were derived from 5,102 UKPDS participants with newly diagnosed type 2 diabetes (aged 25–65) plus 4,031 survivors in 10-year post-trial monitoring; external comparison used 3,984 patients from the Lipids in Diabetes Study.
- Multivariate proportional hazards models were fit for complications and death, with internal validation against 25-year observed UKPDS outcomes, plus one-way deterministic sensitivity analysis and 1,000 Monte Carlo replications for life expectancy estimates.
## Limitations
- The paper states that external validation is beyond the scope of this manuscript and will be addressed in future publications.
- The authors note that complications such as hyperglycaemic and hypoglycaemic episodes are not included in the current model.
- The text makes evident that comparisons with UKPDS-OM1 are limited because some endpoint definitions changed (for example, removal of vascular death from MI), and the external LDS dataset had no observed event rates because the study stopped early.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
2 Valid · 0 Not valid · 10 Not checked · 56 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The UKPDS-OM1 was based on trial data collected in the UKPDS up until 1997.”
§ > Introduction
What the sources say
- Partly supportedcites [1] Clarke PM, Gray AM, Briggs A et al (2004) A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 47:1747–1759 sourceExperimental — accuracy not yet measured
Our copy confirms the first half of the attribution: the model described (UKPDS no. 68, later dubbed UKPDS-OM1) was fitted on UKPDS trial data — Results state 'median follow-up time of patients in the UKPDS was 10.3 years with 39 460 person-years of follow-up data available for model fitting' in 3,642 patients, and Subjects and methods give recruitment between 1977 and 1991. However, no passage in our copy states a calendar cut-off of 1997 for the data (searched: '1997', 'last patient last visit / study closed / data cut-off', 'cut-off date'); the specific end-date element of the claim is therefore not supported by this source, only implied by the follow-up figures. Nothing in our copy contradicts a 1997 end-point. (LLM, conf=0.68)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“providing double the number of events, greater precision and a larger number of significant covariates.”
- Also stated in: § Risk equations · plain
“In general, there were more significant covariates in the new set of event equations. Comparing the seven common event equations across both models, UKPDS-OM1 equations had approximately five, whereas UKPDS-OM2 equations have a mean of 11 covariates per equation (ESM Table 3).”
§ > P. M. Clarke
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Risk equations · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For the cohort as a whole, fewer events were predicted by UKPDS-OM2 than by UKPDS-OM1”
§ > Comparison of UKPDS-OM1 and UKPDS-OM2
plainn = 3,984- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The new model, UKPDS-OM2, is internally valid over 25 years and predicts event rates for complications, which are lower than those from the existing model.”
§ > P. M. Clarke
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“providing double the number of events, greater precision and a larger number of significant covariates.”
- Also stated in: § Risk equations · plain
“For each outcome we had at least twice the number of events as used in the estimation of the UKPDS-OM1 risk equations (e.g. 504 stroke events compared with 157 in UKPDS-OM1).”
§ > P. M. Clarke
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Risk equations · plain
43 more claims
Create a free account to see all 68 claims and to verify the 13 references still open.
- It may state two separate claims as one. 14
- Probably not a substantial claim. 10
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The UKPDS-OM employs an integrated system of parametric equations to estimate the absolute risk of the first occurrence of each of seven diabetes related complications (fatal or non-fatal myocardial infarction, other ischemic heart disease, stroke, heart failure, amputation, renal failure, and eye disease) and death based on patient characteristics (e.g. age, gender) and time-varying risk factors”
From Addressing emotional distress to improve outcomes in adults with type 1 diabetes: Protocol for ACT1VATE randomized controlled trial (2024) · cites this paper as [43]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Data from the UKPDS study was used to develop the predictive equations for diabetes-related complications, mortality, and to assign utilities conditional on disease state.”
From Addressing emotional distress to improve outcomes in adults with type 1 diabetes: Protocol for ACT1VATE randomized controlled trial (2024) · cites this paper as [43]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The UKPSD Outcomes Model provides a full set of equation parameters that were derived from bootstrap samples of the original UKPDS population.”
From Addressing emotional distress to improve outcomes in adults with type 1 diabetes: Protocol for ACT1VATE randomized controlled trial (2024) · cites this paper as [43]
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Self-citation10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Self-citationPartial residuals for the proportional hazards regression model
SCHOENFELD, D. (1982) · Biometrika · doi:10.1093/biomet/69.1.239 · Cited by 3,111
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
Diabetes in Asia: Epidemiology, Risk Factors, and Pathophysiology
Chan, J. C. N., Malik, V., Jia, W., Kadowaki, T., Yajnik, C. S., Yoon, K.-H., & Hu, F. B. (2009) · JAMA · doi:10.1001/jama.2009.726 · Cited by 1,997
The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
STEVENS, R. J., KOTHARI, V., ADLER, A. I., & STRATTON, I. M. (2001) · Clinical Science · doi:10.1042/cs20000335 · Cited by 1,084
Briggs, A. H., Weinstein, M. C., Fenwick, E. A. L., Karnon, J., Sculpher, M. J., & Paltiel, A. D. (2012) · Medical Decision Making · doi:10.1177/0272989x12458348 · Cited by 887
Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study
Currie, C. J., Peters, J. R., Tynan, A., Evans, M., Heine, R. J., Bracco, O. L., Zagar, T., & Poole, C. D. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61969-3 · Cited by 874
Briggs, A. H., Weinstein, M. C., Fenwick, E. A. L., Karnon, J., Sculpher, M. J., & Paltiel, A. D. (2012) · Value in Health · doi:10.1016/j.jval.2012.04.014 · Cited by 823
Cited by
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives
Chan, J. C. N., Lim, L.-L., Wareham, N. J., Shaw, J. E., Orchard, T. J., Zhang, P., Lau, E. S. H., Eliasson, B., Kong, A. P. S., Ezzati, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32374-6 · Cited by 793
Self-citationProceedings of the 2004 Winter Simulation Conference, 2004.
(2004) · doi:10.1109/wsc.2004 · Cited by 587
Pan, A., Wang, Y., Talaei, M., & Hu, F. B. (2015) · Circulation · doi:10.1161/circulationaha.115.017926 · Cited by 343
The independent contribution of diabetic foot ulcer on lower extremity amputation and mortality risk
Martins-Mendes, D., Monteiro-Soares, M., Boyko, E. J., Ribeiro, M., Barata, P., Lima, J., & Soares, R. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.04.011 · Cited by 286
Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes
Molitch, M. E., Adler, A. I., Flyvbjerg, A., Nelson, R. G., So, W.-Y., Wanner, C., Kasiske, B. L., Wheeler, D. C., de Zeeuw, D., & Mogensen, C. E. (2015) · Kidney International · doi:10.1038/ki.2014.128 · Cited by 268
Metadata
- Authors
- Hayes, A. J., Leal, J., Gray, A. M., Holman, R. R., & Clarke, P. M.
- Affiliations
- The University of Sydney (AU)
- University of Oxford (GB)
- Churchill Hospital (GB)
- The University of Melbourne (AU)
- Corresponding author
- Hayes, A. J.
- Venue
- Diabetologia
- Published
- 2013-06-22
- Volume
- 56
- Issue
- 9
- Pages
- 1925-1933
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2091237544
- Cited by
- 495
- References
- 30
- Citations by year
- 2026: 36 · 2025: 56 · 2024: 53 · 2023: 42 · 2022: 51 · 2021: 52 · 2020: 46 · 2019: 35 · 2018: 21 · 2017: 28 · 2016: 32 · 2015: 20 · 2014: 19 · 2013: 2
- FWCI
- 19.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0509-10206)
- University of Oxford
- Medical Research Council (87386)
- National Health and Medical Research Council (512463, 571372)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, risk prediction model, proportional hazards model, diabetes complications, all-cause mortality, diabetic ulcers, estimated glomerular filtration rate, internal validation
- MeSH terms
- Adult, Aged, Diabetes Mellitus, Type 2, Female, United Kingdom, Humans, Male, Middle Aged, Models, Theoretical, Prospective Studies, Outcome Assessment, Health Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. https://app.cochat.ai/papers/10.1007/s00125-013-2940-y
- The paper
- Hayes, A. J., Leal, J., Gray, A. M., Holman, R. R., & Clarke, P. M. (2013). UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia. https://doi.org/10.1007/s00125-013-2940-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.